Viking Therapeutics, Inc. (VKTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VKTX Revenue Growth
VKTX Revenue Analysis (2014–2025)
As of May 7, 2026, Viking Therapeutics, Inc. (VKTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, VKTX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), and CGON (+254.7% YoY). Compare VKTX vs KYMR →
VKTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VKTXCurrent | $0 | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 CGON | $4M | +254.7% | - | -4722.1% |
VKTX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-431,000 | - | $-393,342,000 | - |
| 2024 | $0 | - | $0 | - | $-150,921,000 | - |
| 2023 | $0 | - | $0 | - | $-100,827,000 | - |
| 2022 | $0 | - | $0 | - | $-70,355,000 | - |
| 2021 | $0 | - | $0 | - | $-55,682,000 | - |
| 2020 | $0 | - | $0 | - | $-42,662,000 | - |
| 2019 | $0 | - | $-260,000 | - | $-32,686,999 | - |
| 2018 | $0 | - | $0 | - | $-26,161,000 | - |
| 2017 | $0 | - | $0 | - | $-19,070,189 | - |
| 2016 | $0 | - | $0 | - | $-13,847,275 | - |
See VKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VKTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VKTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVKTX — Frequently Asked Questions
Quick answers to the most common questions about buying VKTX stock.
Is VKTX's revenue growth accelerating or slowing?
VKTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is VKTX's long-term revenue growth rate?
Viking Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is VKTX's revenue distributed by segment?
VKTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.